Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | UGT2B17 | O75795 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29325484 | 0.95 | HTR2C (0.41) | KMT2AUGT2B17HTR2CTAS1R3TAS1R1 | |
| SCHEMBL11110438 | 0.89 | HTR2C (0.45) | HTR2CTAS1R3TAS1R1TAS1R2OPRM1 | |
| SCHEMBL1508379 | 0.89 | HTR2C (0.45) | HTR2CTAS1R3TAS1R1TAS1R2OPRM1 | |
| SCHEMBL1508419 | 0.89 | HTR2C (0.45) | HTR2CTAS1R3TAS1R1TAS1R2OPRM1 | |
| SCHEMBL454127 | 0.79 | ADRA2A (0.51) | KMT2AUGT2B17TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12014020 | 0.79 | UGT2B17 (0.58) | KMT2AUGT2B17HTR2CTAS1R3TAS1R1 | |
| SCHEMBL29644747 | 0.79 | ADRA2A (0.51) | KMT2AUGT2B17TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1151017 | 0.78 | HTR2C (0.42) | HTR2CTAS1R3TAS1R1TAS1R2OPRM1 | |
| SCHEMBL13974016 | 0.78 | KMT2A (0.44) | KMT2AUGT2B17BRD3ACHEGRM5 | |
| SCHEMBL2422836 | 0.78 | UGT2B17 (0.47) | KMT2AUGT2B17TAS1R3TAS1R1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| CN-106983751-B | Bicyclic substituted uracils and their use | 拜耳医药股份有限公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-9949978-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| US-9949977-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-24 | — | — | US | disclosed |
| EP-3045456-B1 | BICYCLIC SUBSTITUTED URACILS AND THEIR USE | Bayer Pharma AG (DE) | 2017-10-25 | — | — | EP | disclosed |
| US-20170267648-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-21 | — | — | US | disclosed |
| US-9751843-B2 | Substituted uracils and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-05 | — | — | US | disclosed |
| US-9695131-B2 | Substituted uracils as chymase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-04 | — | — | US | disclosed |
| EP-2847190-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167495-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-14 | — | — | WO | disclosed |
| EP-0230967-B1 | BENZAZECINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1991-10-23 | — | — | EP | disclosed |
| CN-1013111-B | The method for preparing Benzazecin derivative | HOFFMANN LA ROCHE (CH) | 1991-07-10 | — | — | CN | disclosed |
| US-4957911-A | LEARNING ENHANCEMENT | HOFFMANN-LA ROCHE INC. (US) | 1990-09-18 | — | — | US | disclosed |
| US-4876340-A | Benzazecine derivatives for cognitive and memory functions | HOFFMANN-LA ROCHE INC. (US) | 1989-10-24 | — | — | US | disclosed |
| US-4749791-A | Benzo[f]quinoline intermediates | HOFFMANN-LA ROCHE INC. (US) | 1988-06-07 | — | — | US | disclosed |
| US-4732979-A | CEREBRAL INSUFFICIENCY | HOFFMANN-LA ROCHE INC. (US) | 1988-03-22 | — | — | US | disclosed |
| CN-87100312-A | Benzacyclodecane derivatives | — | 1987-09-09 | — | — | CN | disclosed |
| EP-0230967-A2 | Benzazecine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267648-A1 | SUBSTITUTED URACILS AS CHYMASE INHIBITORS | CMA1, UNG, TYMP | KMT2A 3644/4885UGT2B17 1271/4885HTR2C 2976/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | KMT2A 2888/4885UGT2B17 184/4885HTR2C 3534/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | KMT2A 2888/4885UGT2B17 184/4885HTR2C 3534/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | KMT2A 2888/4885UGT2B17 184/4885HTR2C 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.